Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Klaria Pharma Holding

0.50 SEK+2.03 %13.11. klo 18.29
Less than 1K followers

KLAR

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
+2.03 %
+0.60 %
-45.43 %
-33.51 %
-24.62 %
+3.51 %
+66.66 %
-91.79 %
-89.02 %

Klaria Pharma Holding operates in the pharmaceutical industry. The business is focused on developing and commercializing solutions in the therapeutic areas of migraine and cancer-related pain. The technology is based on the company's drug-delivery platform, where the product consists of an alginate-based polymer film. The film is attached to the patient's oral mucosa, which enables the distribution of drugs in the body. The headquarters are located in Uppsala.

Read more
Market cap
246.96M SEK
Turnover
101.67K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
26.11.
2026

Interim report Q3'26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release13.11.2026 klo 19.45

Klaria Pharma Holding AB: Klaria announces the final outcome of its rights issue of units, raising approximately SEK 111.1 million before issue costs, of which approximately SEK 37.3 million will be paid by way of set-off

Klaria Pharma Holding
Press release06.11.2026 klo 15.20

Klaria Pharma Holding AB: Klaria announces last subscription date in the Company's rights issue

Klaria Pharma Holding
Press release05.11.2026 klo 21.26

Klaria Pharma: The company's present value is approx. SEK 812 million in external valuation, corresponding to approx. SEK 1.88 per share after completion of the rights issue

Klaria Pharma Holding

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release30.10.2026 klo 09.30

Klaria Pharma Holding AB: Klaria advances collaboration with BDO's Life Science M&A team through launch in Europe and completed strategic US plan

Klaria Pharma Holding
Press release26.10.2026 klo 09.30

Klaria Pharma Holding AB: Klaria publishes digital Q&A session with the company's CEO and chairman of the board

Klaria Pharma Holding
Regulatory press release22.10.2026 klo 14.09

Klaria Pharma Holding AB: Klaria receives additional subscription commitments and extends the subscription period in the Company's rights issue

Klaria Pharma Holding
Press release22.10.2026 klo 09.30

Klaria Pharma Holding AB: Klaria plans digital Q&A session with the company's CEO and chairman of the board

Klaria Pharma Holding
Press release20.10.2026 klo 16.03

Klaria Pharma Holding AB: Klaria's chairman interviewed on the upcoming European launch of SAF and the potential in the U.S.

Klaria Pharma Holding
Press release16.10.2026 klo 09.30

Klaria Pharma: External valuation estimates peak sales for Sumatriptan Alginate Film at approx. USD 500 million per year

Klaria Pharma Holding
Regulatory press release13.10.2026 klo 19.11

Klaria Pharma Holding AB: KLARIA PHARMA PUBLISHES PROSPECTUS IN CONNECTION WITH RIGHTS ISSUE OF APPROXIMATELY SEK 147.6 MILLION

Klaria Pharma Holding
Regulatory press release08.10.2026 klo 11.14

Klaria Pharma Holding AB: Klaria has secured subscription and underwriting commitments equivalent to approximately 75.3 percent of the rights offering, as well as bridge financing of approximately SEK 30.7 million

Klaria Pharma Holding
Regulatory press release05.10.2026 klo 14.36

Report from Extraordinary General Meeting of Klaria Pharma Holding AB (publ)

Klaria Pharma Holding
Regulatory press release14.09.2026 klo 13.58

Klaria Pharma Holding AB: Documents for the extraordinary general meeting will be available no later than September 21, 2026.

Klaria Pharma Holding
Press release07.09.2026 klo 21.11

Klaria Pharma Holding AB: Klaria and RTHS enter collaboration agreement for the development of early migraine detection and treatment

Klaria Pharma Holding
Regulatory press release01.09.2026 klo 09.34

Correction - New Report Version: Klaria Interim Report Q2 2026

Klaria Pharma Holding
Regulatory press release01.09.2026 klo 05.10

Summons to extraordinary general meeting of Klaria Pharma Holding AB (publ)

Klaria Pharma Holding
Regulatory press release01.09.2026 klo 05.00

Klaria Pharma Holding AB (publ) calls an Extraordinary General Meeting to resolve on a Rights Issue of units and an amendment of the Articles of Association

Klaria Pharma Holding
Regulatory press release01.09.2026 klo 01.31

Correction: Klaria interm report Q2 2026

Klaria Pharma Holding
Regulatory press release01.09.2026 klo 00.56

Klaria Pharma Holding AB: Klaria Inerim Report Q2 2026

Klaria Pharma Holding
Regulatory press release26.08.2026 klo 12.14

Klaria Pharma Holding AB: Klaria reschedules quarterly report date

Klaria Pharma Holding